ID
45976
Descrição
Principal Investigator: Dan Roden, MD, Vanderbilt University Medical Center, Nashville, TN, USA MeSH: Acute Kidney Injury https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000894 The goal of this study was to identify genetic variants associated with risk for acute kidney injury (AKI) in patients being treated with vancomycin and genetic variants associated with variability in vancomycin pharmacokinetics. AKI is a common adverse drug event and known complication of vancomycin therapy. Known risk factors fail to accurately predict renal toxicity. Our hypothesis, that genetic variants modify the risk of AKI, was tested by performing genome-wide association and linear regression in 429 patients of European descent using the outcome of peak serum creatinine while on vancomycin. We also tested the hypothesis that genetic variants associate with vancomycin pharmacokinetics, using vancomycin trough levels and calculated renal elimination rate constant as outcomes.
Link
Palavras-chave
Versões (1)
- 02/04/2024 02/04/2024 - Madita Rudolph
Titular dos direitos
Dan Roden, MD, Vanderbilt University Medical Center, Nashville, TN, USA
Transferido a
2 de abril de 2024
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
dbGaP phs000894 Genome Wide Study of Vancomycin
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject - Consent - Affection Status Information (All participating subjects are cases - on Vancomycin therapy)
- Subject - Sample Mapping
- The dataset provides data of the quantitative outcome variable (i.e. highest serum creatinine levels measured in the first 2 weeks of intravenous vancomycin therapy, after at least three doses administered), and basic socio-demographic information (age, gender, race).
- Sample - Attribute Information
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject - Consent - Affection Status Information (All participating subjects are cases - on Vancomycin therapy)
- Subject - Sample Mapping
- The dataset provides data of the quantitative outcome variable (i.e. highest serum creatinine levels measured in the first 2 weeks of intravenous vancomycin therapy, after at least three doses administered), and basic socio-demographic information (age, gender, race).
- Sample - Attribute Information
C0680251 (UMLS CUI [1,2])
C0087111 (UMLS CUI [1,2])
C0042313 (UMLS CUI [1,3])
C3174092 (UMLS CUI [1,4])
C0086749 (UMLS CUI [1,5])
C1301725 (UMLS CUI [1,6])
C0680251 (UMLS CUI [2,1])
C0001779 (UMLS CUI [2,2])
C0015031 (UMLS CUI [2,3])
C0034378 (UMLS CUI [2,4])